Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PET policy

This article was originally published in The Gray Sheet

Executive Summary

CMS is considering whether it should alter its approach to coverage of positron emission tomography for cancer to make it more of an all-cancers-or-none strategy. The current framework requires consideration, on a cancer-by-cancer basis, of whether the technique is reasonable and necessary for diagnosis, staging, restaging and monitoring response to treatment, but the agency says it has received public input suggesting that an "omnibus" consideration might be better. The reassessment is part of CMS' ongoing process to consider whether evidence collection requirements established in 2005 as a condition for national coverage for use of PET in nine cancers are still necessary. The consideration has now been expanded to all solid tumors. In August, an advisory committee recommended that the data collection mandate was still needed (1"The Gray Sheet" Aug. 25, 2008, p. 15)

You may also be interested in...



MedCAC Says PET Data Is Too Weak To Remove Registry Requirement

CMS should maintain its data collection requirements for coverage of positron emission tomography for nine cancers, because the evidence linking PET to improved outcomes is still weak, the Medicare Evidence Development and Coverage Advisory Committee concluded at its Aug. 20 meeting

Butterfly Network’s CEO Sees Blank Check Deal As Path To ‘Democratize’ Portable Imaging Platform

Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.

Regenerative Medicine Comes Of Age – In The Age Of COVID-19

Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel